Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathways.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
30 04 2021
Historique:
received: 23 12 2020
accepted: 08 04 2021
revised: 07 04 2021
entrez: 1 5 2021
pubmed: 2 5 2021
medline: 6 10 2021
Statut: epublish

Résumé

Serum deprivation-response protein (SDPR), a phosphatidylserine-binding protein, which is known to have a promising role in caveolar biogenesis and morphology. However, its function in hepatocellular carcinoma (HCC) was still largely unknown. In this study, we discussed the characterization and identification of SDPR, and to present it as a novel apoptosis candidate in the incidence of HCC. We identified 81 HCC cases with lower SDPR expression in the tumor tissues with the help of qRT-PCR assay, and lower SDPR expression was potentially associated with poor prognostication. The phenotypic assays revealed that cell proliferation, invasion, and migration were profoundly connected with SDPR, both in vivo and in vitro. The data obtained from the gene set enrichment analysis (GSEA) carried out on the liver hepatocellular carcinoma (LIHC), and also The Cancer Genome Atlas (TCGA) findings indicated that SDPR was involved in apoptosis and flow cytometry experiments further confirmed this. Furthermore, we identified the interaction between SDPR and apoptosis signal-regulating kinase 1 (ASK1), which facilitated the ASK1 N-terminus-mediated dimerization and increased ASK1-mediated signaling, thereby activating the JNK/p38 mitogen-activated protein kinases (MAPKs) and finally enhanced cell apoptosis. Overall, this work identified SDPR as a tumor suppressor, because it promoted apoptosis by activating ASK1-JNK/p38 MAPK pathways in HCC.

Identifiants

pubmed: 33931585
doi: 10.1038/s41419-021-03711-x
pii: 10.1038/s41419-021-03711-x
pmc: PMC8087765
doi:

Substances chimiques

Biomarkers, Tumor 0
CAVIN2 protein, human 0
Phosphate-Binding Proteins 0
JNK Mitogen-Activated Protein Kinases EC 2.7.11.24
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24
MAP Kinase Kinase Kinase 5 EC 2.7.11.25
MAP3K5 protein, human EC 2.7.11.25

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

425

Références

J Cell Physiol. 2002 Apr;191(1):95-104
pubmed: 11920685
Oncologist. 2014 Nov;19(11):1169-78
pubmed: 25223462
Immunol Rev. 2009 Mar;228(1):212-24
pubmed: 19290930
Mol Cell Biol. 2007 Dec;27(23):8152-63
pubmed: 17724081
Nephron. 2015;129(1):29-33
pubmed: 25531162
Aging (Albany NY). 2016 Apr;8(4):603-19
pubmed: 27019364
Cancer Sci. 2008 Jul;99(7):1326-33
pubmed: 18422756
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):638-43
pubmed: 26739564
Arch Toxicol. 2015 Jun;89(6):867-82
pubmed: 25690731
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3172-3179
pubmed: 31352804
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Mol Cell Biol. 2008 Mar;9(3):231-41
pubmed: 18073771
Lancet. 2003 Dec 6;362(9399):1907-17
pubmed: 14667750
Annu Rev Pharmacol Toxicol. 2008;48:199-225
pubmed: 17883330
Science. 1997 Jan 3;275(5296):90-4
pubmed: 8974401
Genes Dev. 2002 Jun 1;16(11):1345-55
pubmed: 12050113
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Physiol Biochem. 2016;39(3):950-60
pubmed: 27513662
J Biol Chem. 2014 Aug 29;289(35):24463-74
pubmed: 25037217
Front Oncol. 2011 Aug 27;1:23
pubmed: 22655234
Nat Cell Biol. 2009 Jul;11(7):807-14
pubmed: 19525939
J Vasc Interv Radiol. 2019 Mar;30(3):349-357.e2
pubmed: 30819477
Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3030-3038
pubmed: 27693599
Antioxid Redox Signal. 2013 Nov 1;19(13):1539-605
pubmed: 23397885
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2096-E2105
pubmed: 28242696
Cells. 2019 Oct 11;8(10):
pubmed: 31614673
Curr Cancer Drug Targets. 2011 Oct;11(8):944-53
pubmed: 21834756
Hepatology. 2011 Jul;54(1):185-95
pubmed: 21488081
Science. 1995 Mar 10;267(5203):1456-62
pubmed: 7878464
Mol Ther. 2019 Jun 5;27(6):1166-1182
pubmed: 30879950
J Hepatol. 2016 Jun;64(6):1365-77
pubmed: 26860405

Auteurs

Xi Chen (X)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Weijie Ma (W)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Ye Yao (Y)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Qi Zhang (Q)

Department of General Medicine, Renmin Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Jinghua Li (J)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Xiaoling Wu (X)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Chengjie Mei (C)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Xiang Jiang (X)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Yiran Chen (Y)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Ganggang Wang (G)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Kunlei Wang (K)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Yingyi Liu (Y)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Yonghua Guo (Y)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.

Zhisu Liu (Z)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. liuzs53@sina.com.

Yufeng Yuan (Y)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. yuanyf1971@whu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH